Resveratrol inhibits renal fibrosis in the obstructed kidney: Potential role in deacetylation of Smad3

American Journal of Pathology

Volumn 177, Issue 3, 2010, Pages 1065-1071

  Li, Jinhua ^a   Qu, Xinli ^a   Ricardo, Sharon D ^a   Bertram, John F ^a   Nikolic Paterson, David J ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 4; DIMETHYL SULFOXIDE; FIBRONECTIN; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE; RESVERATROL; SIRTUIN 1; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

ACETYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DEACETYLATION; FIBROBLAST; FIBROSING ALVEOLITIS; IMMUNOPRECIPITATION; IN VITRO STUDY; INHIBITION KINETICS; KIDNEY FIBROSIS; KIDNEY TUBULE EPITHELIUM; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; URETER OBSTRUCTION; WESTERN BLOTTING;

EID: 77956531086     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2010.090923     Document Type: Article

References (23)

1. Flanders KC: Smad3 as a mediator of the fibrotic response. Int J Exp Pathol 2004, 85:47-64
2. Wang W, Koka V, Lan HY: Transforming growth factor-beta and Smad signalling in kidney diseases. Nephrology 2005, 10:48-56 (Pubitemid 40349406)
3. Sato M, Muragaki Y, Saika S, Roberts AB, Ooshima A: Targeted disruption of TGF-β1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J Clin Invest 2003, 112:1486-1494 (Pubitemid 38056275)
4. Fujimoto M, Maezawa Y, Yokote K, Joh K, Kobayashi K, Kawamura H, Nishimura M, Roberts AB, Saito Y, Mori S: Mice lacking Smad3 are protected against streptozotocin-induced diabetic glomerulopathy. Biochem Biophys Res Commun 2003, 305:1002-1007 (Pubitemid 36597863)
5. Li JH, Huang XR, Zhu HJ, Oldfield M, Cooper M, Truong LD, Johnson RJ, Lan HY: Advanced glycation end products activate Smad signaling via TGF-beta-dependent and independent mechanisms: implications for diabetic renal and vascular disease. FASEB J 2004, 18:176-178
6. Li J, Campanale NV, Liang RJ, Deane JA, Bertram JF, Ricardo SD: Inhibition of p38 mitogen-activated protein kinase and transforming growth factor-beta1/Smad signaling pathways modulates the development of fibrosis in adriamycin-induced nephropathy. Am J Pathol 2006, 169:1527-1540 (Pubitemid 351181986)
7. Simonsson M, Kanduri M, Grönroos E, Heldin CH, Ericsson J: The DNA binding activities of Smad2 and Smad3 are regulated by coactivator- mediated acetylation. J Biol Chem 2006, 281:39870-33980 (Pubitemid 46041790)
8. Inoue Y, Itoh Y, Abe K, Okamoto T, Daitoku H, Fukamizu A, Onozaki K, Hayashi H: Smad3 is acetylated by p300/CBP to regulate its transactivation activity. Oncogene 2007, 26:500-508 (Pubitemid 46160964)
9. Yang X, and Seto E: Lysine acetylation: codified crosstalk with other posttranslational modifications. Mol Cell 2008, 31:449-461
10. Roth SY, Denu JM, Allis CD: Histone acetyltransferases. Annu Rev Biochem 2001, 70:81-120
11. Bhattacharyya S, Ghosh AK, Pannu J, Mori Y, Takagawa S, Chen G, Trojanowska M, Gilliam AC, Varga J: Fibroblast expression of the coactivator p300 governs the intensity of profibrotic response to transforming growth factor beta. Arthritis Rheum 2005, 52:1248-1258 (Pubitemid 40530133)
12. Ghosh AK, Varga J: The transcriptional coactivator and acetyltransferase p300 in fibroblast biology and fibrosis. J Cell Physiol 2007, 213:663-671
13. Guarente L: Cell biology. Hypoxic hookup. Science 2009, 324:1281-1282
14. Baur JA, Sinclair DA: Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 2006, 5:493-506
15. Cadenas S, Barja G: Resveratrol, melatonin, vitamin E, and PBN protect against renal oxidative DNA damage induced by the kidney carcinogen KBrO3. Free Radic Biol Med 1999, 26:1531-1537 (Pubitemid 29302287)
16. Giovannini L, Migliori M, Longoni BM, Das DK, Bertelli AA, Panichi V, Filippi C, Bertelli A: Resveratrol, a polyphenol found in wine, reduces ischemia reperfusion injury in rat kidneys. J Cardiovasc Pharmacol 2001, 37:262-270 (Pubitemid 32193504)
17. Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Frye RA, Mayo MW: Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 2004, 23:2369-2380 (Pubitemid 38954844)
18. Stewart JR, O'Brian CA: Resveratrol antagonizes EGFR-dependent Erk1/2 activation in human androgen-independent prostate cancer cells with associated isozyme-selective PKC alpha inhibition. Invest New Drugs 2004, 22:107-117
19. Huang Z, Wang C, Wei L, Wang J, Fan Y, Wang L, Wang Y, Chen T: Resveratrol inhibits EMMPRIN expression via P38 and ERK1/2 pathways in PMA-induced THP-1 cells. Biochem Biophys Res Commun 2008, 374:517-521
20. Kundu JK, Shin YK, Kim SH, Surh YJ: Resveratrol inhibits phorbol ester-induced expression of COX-2 and activation of NF-kappaB in mouse skin by blocking IkappaB kinase activity. Carcinogenesis 2006, 27:1465-1474
21. Bhardwaj A, Sethi G, Vadhan-Raj S, Bueso-Ramos C, Takada Y, Gaur U, Nair AS, Shishodia S, Aggarwal BB: Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood 2007, 109:2293-2302 (Pubitemid 46425866)
22. Venkatesan B, Ghosh-Choudhury N, Das F, Mahimainathan L, Kamat A, Kasinath BS, Abboud HE, Choudhury GG: Resveratrol inhibits PDGF receptor mitogenic signaling in mesangial cells. role of PTP1B. FASEB J 2008, 22:3469-3482
23. Kume S, Haneda M, Kanasaki K, Sugimoto T, Araki S, Isshiki K, Isono M, Uzu T, Guarente L, Kashiwagi A, Koya D: SIRT1 inhibits transforming growth factor beta-induced apoptosis in glomerular mesangial cells via Smad7 deacetylation. J Biol Chem 2007, 282:151-158 (Pubitemid 47076643)